Clinical trials: Uncomplicated P. Falciparum Malaria
Malaria
Ethiopia Malaria Therapeutic Efficacy Study
In this stdy, patients aged above 6 months with symptomatic malaria presenting to health centers will be enrolled for treatment with artemether-lumefantrine for P.
- Trial name
- NCT01052584
- Testing
- Chloroquine- P. vivax, Artemether-Lumefantrine: P. vivax, Artemether-lumefantrine: P. falciparum
- Where
- 2 sites in Ethiopia
- Volunteers
- 354 people
- Sponsor
- Centers for Disease Control and Prevention
Uncomplicated P. Falciparum Malaria
SPK Study in Afghanistan
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine. In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria…
- Trial name
- NCT01707199
- Testing
- Artesunate + Sulphadoxine-pyrimethamine
- Where
- Afghanistan
- Volunteers
- 83 people
- Sponsor
- University of Oxford
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Plasmodium Falciparum Infection
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms.
- Trial name
- AL3vs5 (NCT02020330)
- Testing
- Artemether-lumefantrine 3 days, Artemether-lumefantrine 5 days
- Where
- Burma
- Volunteers
- 150 people
- Sponsor
- University of Oxford
Fever, Malaria
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children
The main objective is to compare the safety and efficacy of 4 artemisinin-based combinations (ACT) [amodiaquine-artesunate (AQ+AS), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and chlorproguanil/dapsone…
- Trial name
- NCT00393679
- Testing
- amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL)
- Where
- 8 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 4,112 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Riamet® or Malarone® are both recommended as the first line treatment for uncomplicated malaria in France, according to the French consensus Conference revised in 2007 on the treatment of imported malaria.
- Trial name
- MalaRia (NCT01150344)
- Testing
- Malarone (atovaquone + proguanil combination), RIAMET (artemether + LUMEFANTRIN combination)
- Where
- France
- Volunteers
- 317 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malaria
Artemisinin Resistance in Bangladesh
A randomized, controlled clinical trial conducted in Southeastern Bangladesh using artesunate monotherapy to determine the baseline sensitivity of P. falciparum to artemisinins.
- Trial name
- NCT00639873
- Testing
- Artesunate, quinine-doxycycline
- Where
- Bangladesh
- Volunteers
- 126 people
- Sponsor
- Medical University of Vienna
Malaria,Falciparum, Malaria
Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia
The primary goal of this study is to quantify the benefit of adding artesunate to amodiaquine in treating patients with uncomplicated P. falciparum malaria, in a low transmission area in Colombia.
- Conditions
- Malaria,Falciparum, Malaria, Antimalarials
- Trial name
- NCT00378625
- Testing
- Artesunate
- Where
- Colombia
- Volunteers
- 360 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Falciparum Malaria
Tracking Resistance to Artemisinin (TRAC)
Because the artemisinins are the most potent antimalarial drugs, the reduction in parasite numbers is rapid. Therefore, early measures of reducing parasite counts are needed.
- Trial name
- TRAC (NCT01350856)
- Testing
- Artesunate 2, Artesunate 4
- Where
- 19 sites in Bangladesh, Burma and 8 more
- Volunteers
- 1,700 people
- Sponsor
- University of Oxford
Malaria
MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria
The present proof-of-concept Phase IIa study aims to confirm, in patients, the observed activity of MMV390048 against P. falciparum in pre-clinical models and the human Induced Blood-Stage Malaria (IBSM) challenge model, and to…
- Trial name
- NCT02880241
- Testing
- MMV390048
- Where
- 2 sites in Ethiopia
- Volunteers
- 8 people
- Sponsor
- Medicines for Malaria Venture
Uncomplicated Plasmodium Falciparum Malaria
Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.
A randomised, double-blind single-dose study to determine the efficacy, safety, tolerability and pharmacokinetics of OZ439 (artefenomel) in combination with piperaquine (PQP) in patients > 0.5 years and <= 70 years of age with…
- Trial name
- NCT02083380
- Testing
- Artefenomel 800mg: piperaquine 640mg, Artefenomel 800mg: piperaquine 960mg, Artefenomel 800mg: piperaquine 1440mg
- Where
- 9 sites in Benin, Burkina Faso and 5 more
- Volunteers
- 448 people
- Sponsor
- Medicines for Malaria Venture
Plasmodium Falciparum Infection
Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Primary objective: To assess the Day 28 efficacy defined as the percentage of patients with no parasitic recrudescence, of 3 treatment groups - 3 dose levels of ferroquine associated with artesunate - for a 3-day treatment.
- Trial name
- FARM (NCT00988507)
- Testing
- Ferroquine (SSR97193), artesunate
- Where
- 10 sites in Benin, Burkina Faso and 4 more
- Volunteers
- 440 people
- Sponsor
- Sanofi
Malaria
A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609
- Trial name
- NCT01836458
- Testing
- KAE609
- Where
- Vietnam
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period
A community-based, open-label, cluster-randomised longitudinal study in which children are randomized according to village health worker catchment areas comparing the safety and effectiveness of repeated treatments with…
- Trial name
- NCT01038063
- Testing
- Artemether-lumefantrine combination
- Where
- Malawi
- Volunteers
- 1,200 people
- Sponsor
- Liverpool School of Tropical Medicine
Plasmodium Falciparum Infection
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To determine whether a single dose combination of OZ439 (Artefenomel)/FQ (Ferroquine) was an efficacious treatment for uncomplicated Plasmodium falciparum malaria in adults and children.
- Trial name
- FALCI (NCT02497612)
- Testing
- Ferroquine SSR97193, Artefenomel
- Where
- 12 sites in Benin, Burkina Faso and 5 more
- Volunteers
- 377 people
- Sponsor
- Sanofi
Plasmodium Falciparum Infection, Plasmodium Vivax Infection
Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria
This is an observational safety and efficacy study on dihydroartemisinin-piperaquine in Timika, Indonesia with a 42 day follow up period.
- Trial name
- NCT02353494
- Testing
- Dihydroartemisinin-Piperaquine
- Where
- Indonesia
- Volunteers
- 130 people
- Sponsor
- Menzies School of Health Research
Malaria
Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients
The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate…
- Trial name
- NCT00541385
- Testing
- pyronaridine artesunate, arthemeter lumefantrine
- Where
- 8 sites in Burkina Faso, Côte d’Ivoire and 6 more
- Volunteers
- 535 people
- Sponsor
- Medicines for Malaria Venture
Malaria, Falciparum
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.
This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.
- Trial name
- NCT00386763
- Testing
- Artemether-lumefantrine
- Where
- 5 sites in Benin, Kenya and 3 more
- Volunteers
- 890 people
- Sponsor
- Novartis
Plasmodium Falciparum Malaria
Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status
The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria.
- Trial name
- NCT00304980
- Testing
- ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE
- Where
- Zambia
- Volunteers
- 3,000 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
Harmonized AS/MQ Efficacy Study - Thailand
The purposes of this study is to determine parasitological clearance rates by microscopy for the 72-hour period after first artesunate dose in subjects with uncomplicated P. falciparum malaria.
- Trial name
- NCT02052323
- Testing
- Artesunate/mefloquine (AS/MQ)
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand